Owen A Ross

List of Publications by Year in Descending Order

210 papers	11,187 citations	52 h-index	98 g-index
216 ext. papers	13,179 ext. citations	7.8 avg, IF	5.48 L-index

#	Paper	IF	Citations
210	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer's disease. *Nature Communications*, **2021**, 12, 2311	17.4	10
209	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Annals of Neurology*, **2021**, 90, 76-88	9.4	9
208	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. *Nature Communications*, **2021**, 12, 3452	17.4	10
207	Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa. *Movement Disorders*, **2021**, 36, 2442-2444	7	2
206	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. *Annals of Neurology*, **2021**, 89, 520-533	9.4	6
205	Frequency of spinocerebellar ataxia mutations in patients with multiple system atrophy. *Clinical Autonomic Research*, **2021**, 31, 117-125	4.3	2
204	Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease. *Neurology*, **2021**, 96, e1755-e1760	6.5	
203	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nature Genetics*, **2021**, 53, 294-303	36.3	31
202	-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. *Science Translational Medicine*, **2021**, 13, eabc9375	17.5	6
201	Tau and MAPT genetics in tauopathies and synucleinopathies. *Parkinsonism and Related Disorders*, **2021**, 90, 142-154	3.6	3
200	Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease. *Movement Disorders*, **2021**,	7	0
199	Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy. *Movement Disorders*, **2020**, 35, 890-894	7	1
198	APOE4 exacerbates -synuclein pathology and related toxicity independent of amyloid. *Science Translational Medicine*, **2020**, 12,	17.5	40
197	LRP10 variants in progressive supranuclear palsy. *Neurobiology of Aging*, **2020**, 94, 311.e5-311.e10	5.6	3
196	Plasma neurofilament light predicts mortality in patients with stroke. *Science Translational Medicine* , **2020**, 12,	17.5	20
195	Association of MAPT subhaplotypes with clinical and demographic features in Parkinson's disease. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1557-1563	5.3	2
194	Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures. *Acta Neuropathologica Communications*, **2020**, 8, 162	7.3	6

193	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. *Acta Neuropathologica*, **2019**, 138, 237-250	14.3	50
192	The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects. *Neurochemistry International*, **2019**, 129, 104495	4.4	12
191	Association of MAPT H1 subhaplotypes with neuropathology of lewy body disease. *Movement Disorders*, **2019**, 34, 1325-1332	7	6
190	X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia. *Journal of Neuropathology and Experimental Neurology*, **2019**, 78, 460-466	3.1	5
189	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. *JAMA Neurology*, **2019**, 76, 710-717	17.2	23
188	Heritability and genetic variance of dementia with Lewy bodies. *Neurobiology of Disease*, **2019**, 127, 492-501	7.9	15
187	Parkinson's disease in Nigeria: A review of published studies and recommendations for future research. *Parkinsonism and Related Disorders*, **2019**, 62, 36-43	3.6	6
186	Partial loss of function of colony-stimulating factor 1 receptor in a patient with white matter abnormalities. *European Journal of Neurology*, **2018**, 25, 875-881	6	7
185	TDP-43 pathology in multiple system atrophy: colocalization of TDP-43 and □synuclein in glial cytoplasmic inclusions. *Neuropathology and Applied Neurobiology*, **2018**, 44, 707-721	5.2	19
184	Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. *JAMA Neurology*, **2018**, 75, 860-875	17.2	56
183	Multiple system atrophy and apolipoprotein E. *Movement Disorders*, **2018**, 33, 647-650	7	11
182	Comparison of clinical features among Parkinson's disease subtypes: A large retrospective study in a single center. *Journal of the Neurological Sciences*, **2018**, 386, 39-45	3.2	24
181	Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. *Molecular Neurodegeneration*, **2018**, 13, 37	19	28
180	□4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. *Neurology*, **2018**, 91, e1182-e1195	6.5	77
179	A novel link between trafficking and Lewy body disorders. *Lancet Neurology, The*, **2018**, 17, 571-573	24.1	0
178	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. *PLoS Medicine*, **2018**, 15, e1002487	11.6	77
177	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. *Acta Neuropathologica*, **2018**, 136, 389-404	14.3	27
176	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 64-74	24.1	121

175	Atypical parkinsonian syndromes: a general neurologistR3 perspective. *European Journal of Neurology*, **2018**, 25, 41-58	6	27
174	Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons. *American Journal of Human Genetics*, **2018**, 103, 874-892	11	15
173	LRP10 in Esynucleinopathies. *Lancet Neurology, The*, **2018**, 17, 1033-1034	24.1	9
172	LRP10 in Esynucleinopathies. *Lancet Neurology, The*, **2018**, 17, 1032-1033	24.1	9
171	Sex and age interact to determine clinicopathologic differences in AlzheimerR3 disease. *Acta Neuropathologica*, **2018**, 136, 873-885	14.3	36
170	Full sequencing and haplotype analysis of MAPT in ParkinsonR3 disease and rapid eye movement sleep behavior disorder. *Movement Disorders*, **2018**, 33, 1016-1020	7	19
169	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. *Autophagy*, **2018**, 14, 1404-1418	10.2	47
168	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. *Acta Neuropathologica*, **2017**, 133, 825-837	14.3	58
167	Occurrence of CrohnR3 disease with ParkinsonR3 disease. *Parkinsonism and Related Disorders*, **2017**, 37, 116-117	3.6	22
166	DCTN1-related neurodegeneration: Perry syndrome and beyond. *Parkinsonism and Related Disorders*, **2017**, 41, 14-24	3.6	37
165	Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease. *Movement Disorders*, **2017**, 32, 1584-1593	7	11
164	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. *Lancet Neurology, The*, **2017**, 16, 898-907	24.1	121
163	ParkinsonR3 disease susceptibility variants and severity of Lewy body pathology. *Parkinsonism and Related Disorders*, **2017**, 44, 79-84	3.6	10
162	Heterozygous PINK1 p.G411S increases risk of ParkinsonR3 disease via a dominant-negative mechanism. *Brain*, **2017**, 140, 98-117	11.2	88
161	Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. *Movement Disorders*, **2017**, 32, 115-123	7	34
160	Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy. *Neuropathology and Applied Neurobiology*, **2017**, 43, 200-214	5.2	37
159	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. *JAMA Neurology*, **2016**, 73, 1217-1224	17.2	120
158	LRRK2 variation and dementia with Lewy bodies. *Parkinsonism and Related Disorders*, **2016**, 31, 98-103	3.6	21

157	Identification of genetic modifiers of age-at-onset for familial Parkinson disease. *Human Molecular Genetics*, **2016**, 25, 3849-3862	5.6	37
156	Genome-wide association study in essential tremor identifies three new loci. *Brain*, **2016**, 139, 3163-3169	11.2	57
155	Epigenetic regulation in Parkinson disease. *Acta Neuropathologica*, **2016**, 132, 515-30	14.3	62
154	Rare variants in MC1R/TUBB3 exon 1 are not associated with Parkinson disease. *Annals of Neurology*, **2016**, 79, 331	9.4	7
153	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. *Alzheimer's and Dementia*, **2016**, 12, 1297-1304	1.2	21
152	Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms. *Parkinsonism and Related Disorders*, **2016**, 22, 102-5	3.6	12
151	Genetic susceptibility variants in parkinsonism. *Parkinsonism and Related Disorders*, **2016**, 22 Suppl 1, S7-11	3.6	14
150	-synuclein genetic variability: A biomarker for dementia in Parkinson disease. *Annals of Neurology*, **2016**, 79, 991-9	9.4	64
149	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP-C. *Movement Disorders* , **2016**, 31, 653-62	7	43
148	MAPT haplotype diversity in multiple system atrophy. *Parkinsonism and Related Disorders*, **2016**, 30, 40-5	3.6	18
147	RAB39B gene mutations are not a common cause of Parkinson disease or dementia with Lewy bodies. *Neurobiology of Aging*, **2016**, 45, 107-108	5.6	18
146	Tremor in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2016**, 27, 93-7	3.6	14
145	Modifiers of LRRK2 parkinsonism: new therapeutic targets. *Lancet Neurology, The*, **2016**, 15, 1200-1201	24.1	2
144	Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review. *Neuropathology*, **2016**, 36, 64-76	2	21
143	Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1. *Mayo Clinic Proceedings*, **2015**, 90, 366-71	6.4	10
142	Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer disease spectrum. *Brain*, **2015**, 138, 1370-81	11.2	224
141	TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study. *Parkinsonism and Related Disorders*, **2015**, 21, 306-9	3.6	26
140	Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase Parkin. *Human Mutation*, **2015**, 36, 774-86	4.7	54

139	Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with -synuclein. *Acta Neuropathologica*, **2015**, 130, 93-105	14.3	51
138	VPS35 and DNAJC13 disease-causing variants in essential tremor. *European Journal of Human Genetics*, **2015**, 23, 887-8	5.3	20
137	Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. *Acta Neuropathologica*, **2015**, 129, 53-64	14.3	50
136	(Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. *EMBO Reports*, **2015**, 16, 1114-30	6.5	102
135	Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. *Molecular Neurodegeneration*, **2015**, 10, 46	19	47
134	Low density lipoprotein receptor related protein 1 and 6 gene variants and ischaemic stroke risk. *European Journal of Neurology*, **2015**, 22, 1235-41	6	10
133	DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. *European Journal of Neurology*, **2015**, 22, 1323-5	6	15
132	Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. *JAMA Neurology*, **2015**, 72, 100-5	17.2	191
131	CHCHD2 and Parkinson's disease. *Lancet Neurology, The*, **2015**, 14, 679	24.1	15
130	A novel tau mutation, p.K317N, causes globular glial tauopathy. *Acta Neuropathologica*, **2015**, 130, 199-214	14.3	33
129	A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick Disease. *Journal of Neuropathology and Experimental Neurology*, **2015**, 74, 1042-52	3.1	22
128	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. *Acta Neuropathologica*, **2015**, 130, 877-89	14.3	176
127	Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2015**, 21, 101-5	3.6	29
126	Linking the VPS35 and EIF4G1 pathways in Parkinson's disease. *Neuron*, **2015**, 85, 1-3	13.9	29
125	Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus. *PLoS ONE*, **2015**, 10, e0128586	3.7	
124	Latin America's first case of Perry syndrome and a new treatment option for respiratory insufficiency. *Journal of Neurology*, **2014**, 261, 620-1	5.5	9
123	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. *Neurogenetics*, **2014**, 15, 23-30	3	49
122	Genetic screening and functional characterization of PDGFRB mutations associated with basal ganglia calcification of unknown etiology. *Human Mutation*, **2014**, 35, 964-71	4.7	37

121	DNAJC13 mutations in Parkinson disease. *Human Molecular Genetics*, **2014**, 23, 1794-801	5.6	209
120	Early-onset Parkinson disease due to PINK1 p.Q456X mutation--clinical and functional study. *Parkinsonism and Related Disorders*, **2014**, 20, 1274-8	3.6	25
119	A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study. *Parkinsonism and Related Disorders*, **2014**, 20, 1129-34	3.6	6
118	Chromosome 22q11.2 deletion may contain a locus for recessive early-onset Parkinson disease. *Parkinsonism and Related Disorders*, **2014**, 20, 945-6	3.6	10
117	Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age. *Human Molecular Genetics*, **2014**, 23, 4420-32	5.6	188
116	Three families with Perry syndrome from distinct parts of the world. *Parkinsonism and Related Disorders*, **2014**, 20, 884-8	3.6	19
115	Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson disease. *Neurobiology of Aging*, **2014**, 35, 1958.e1-2	5.6	18
114	Differential clinicopathologic and genetic features of late-onset amnestic dementias. *Acta Neuropathologica*, **2014**, 128, 411-21	14.3	90
113	EIF4G1 gene mutations are not a common cause of Parkinson disease in the Japanese population. *Parkinsonism and Related Disorders*, **2014**, 20, 659-61	3.6	10
112	Analysis of nuclear export sequence regions of FUS-Related RNA-binding proteins in essential tremor. *PLoS ONE*, **2014**, 9, e111989	3.7	8
111	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics*, **2014**, 23, 6139-46	5.6	152
110	Analysis of COQ2 gene in multiple system atrophy. *Molecular Neurodegeneration*, **2014**, 9, 44	19	30
109	Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. *Acta Neuropathologica*, **2014**, 127, 271-82	14.3	60
108	Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson Disease (GEO-PD) Consortium. *Movement Disorders*, **2013**, 28, 1740-4	7	24
107	A prognostic view on the application of individualized genomics in Parkinson disease. *Current Genetic Medicine Reports*, **2013**, 1, 52-57	2.2	11
106	Novel A18T and pA29S substitutions in -synuclein may be associated with sporadic Parkinson disease. *Parkinsonism and Related Disorders*, **2013**, 19, 1057-1060	3.6	51
105	Genetic variants associated with myocardial infarction in the PSMA6 gene and Chr9p21 are also associated with ischaemic stroke. *European Journal of Neurology*, **2013**, 20, 300-8	6	21
104	Analysis of the C9orf72 repeat in Parkinson disease, essential tremor and restless legs syndrome. *Parkinsonism and Related Disorders*, **2013**, 19, 198-201	3.6	35

103	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. *Parkinsonism and Related Disorders*, **2013**, 19, 869-77	3.6	45
102	Investigating the role of FUS exonic variants in essential tremor. *Parkinsonism and Related Disorders* , **2013**, 19, 755-7	3.6	33
101	TARDBP mutations in Parkinson's disease. *Parkinsonism and Related Disorders*, **2013**, 19, 312-5	3.6	31
100	Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. *Acta Neuropathologica*, **2013**, 125, 425-38	14.3	16
99	Common variants within oxidative phosphorylation genes influence risk of ischemic stroke and intracerebral hemorrhage. *Stroke*, **2013**, 44, 612-9	6.7	27
98	NOTCH3 variants and risk of ischemic stroke. *PLoS ONE*, **2013**, 8, e75035	3.7	27
97	LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation. *Movement Disorders*, **2012**, 27, 146-51	7	15
96	Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. *Acta Neuropathologica*, **2012**, 124, 681-92	14.3	79
95	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. *Journal of Medical Genetics*, **2012**, 49, 721-6	5.8	78
94	First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation. *Parkinsonism and Related Disorders*, **2012**, 18, 332-8	3.6	31
93	PARK2 variability in Polish Parkinson's disease patients--interaction with mitochondrial haplogroups. *Parkinsonism and Related Disorders*, **2012**, 18, 520-4	3.6	9
92	Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. *Annals of Neurology*, **2012** , 71, 370-84	9.4	214
91	Angiogenin variation and Parkinson disease. *Annals of Neurology*, **2012**, 71, 725-7; author reply 727-8	9.4	18
90	Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. *Science Translational Medicine*, **2012**, 4, 141ra90	17.5	381
89	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. *Human Molecular Genetics*, **2012**, 21, 3500-12	5.6	174
88	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nature Genetics*, **2011**, 43, 699-705	36.3	386
87	Glucocerebrosidase mutations in diffuse Lewy body disease. *Parkinsonism and Related Disorders*, **2011**, 17, 55-7	3.6	37
86	Human leukocyte antigen variation and Parkinson's disease. *Parkinsonism and Related Disorders*, **2011**, 17, 376-8	3.6	29

85	Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America. *Parkinsonism and Related Disorders*, **2011**, 17, 629-31	3.6	12
84	Ataxin-2 repeat-length variation and neurodegeneration. *Human Molecular Genetics*, **2011**, 20, 3207-12	5.6	128
83	Death-associated protein kinase 1 variation and Parkinson's disease. *European Journal of Neurology*, **2011**, 18, 1090-3	6	4
82	SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. *European Journal of Neurology*, **2011**, 18, 876-81	6	31
81	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. *Lancet Neurology, The*, **2011**, 10, 785-96	24.1	531
80	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. *Lancet Neurology, The*, **2011**, 10, 898-908	24.1	237
79	VPS35 mutations in Parkinson disease. *American Journal of Human Genetics*, **2011**, 89, 162-7	11	618
78	Translation initiator EIF4G1 mutations in familial Parkinson disease. *American Journal of Human Genetics*, **2011**, 89, 398-406	11	213
77	Genetic variants of -synuclein are not associated with essential tremor. *Movement Disorders*, **2011**, 26, 2552-6	7	12
76	Common mitochondrial sequence variants in ischemic stroke. *Annals of Neurology*, **2011**, 69, 471-80	9.4	31
75	Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. *Annals of Neurology*, **2011**, 69, 778-92	9.4	76
74	Functional alteration of PARL contributes to mitochondrial dysregulation in Parkinson's disease. *Human Molecular Genetics*, **2011**, 20, 1966-74	5.6	131
73	Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. *Archives of Neurology*, **2010**, 67, 970-5		49
72	Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. *Neuroscience Letters*, **2010**, 477, 57-60	3.3	16
71	Mitochondrial translation initiation factor 3 polymorphism and Parkinson's disease. *Neuroscience Letters*, **2010**, 486, 228-30	3.3	17
70	LINGO1 rs9652490 is associated with essential tremor and Parkinson disease. *Parkinsonism and Related Disorders*, **2010**, 16, 109-11	3.6	58
69	Histamine N-methyltransferase Thr105Ile is not associated with Parkinson's disease or essential tremor. *Parkinsonism and Related Disorders*, **2010**, 16, 112-4	3.6	18
68	Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease. *Parkinsonism and Related Disorders*, **2010**, 16, 686-7	3.6	29

67	Principal-component analysis for assessment of population stratification in mitochondrial medical genetics. *American Journal of Human Genetics*, **2010**, 86, 904-17	11	38
66	LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. *Neurogenetics*, **2010**, 11, 401-8	3	106
65	Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease. *Mechanisms of Ageing and Development*, **2010**, 131, 210-4	5.6	16
64	Association of pyridoxal kinase and Parkinson disease. *Annals of Neurology*, **2010**, 67, 409-11	9.4	7
63	LRRK2 variation and Parkinson disease in African Americans. *Movement Disorders*, **2010**, 25, 1973-6	7	8
62	Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson disease. *Movement Disorders*, **2010**, 25, 2156-63	7	86
61	Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson disease from North Africa. *Movement Disorders*, **2010**, 25, 2052-8	7	13
60	Calbindin-1 association and Parkinson disease. *European Journal of Neurology*, **2010**, 17, 208-11	6	8
59	Association of the MAPT locus with Parkinson disease. *European Journal of Neurology*, **2010**, 17, 483-6	6	41
58	Genetics of Parkinson disease and essential tremor. *Current Opinion in Neurology*, **2010**, 23, 388-93	7.1	27
57	FGF20 and Parkinson disease: no evidence of association or pathogenicity via alpha-synuclein expression. *Movement Disorders*, **2009**, 24, 455-9	7	38
56	Reported mutations in GIGYF2 are not a common cause of Parkinson disease. *Movement Disorders*, **2009**, 24, 619-20	7	24
55	Expanding the clinical phenotype of SNCA duplication carriers. *Movement Disorders*, **2009**, 24, 1811-9	7	103
54	Alpha-synuclein polymorphisms are associated with Parkinson disease in a Saskatchewan population. *Movement Disorders*, **2009**, 24, 2411-4	7	15
53	Fine-mapping and candidate gene investigation within the PARK10 locus. *European Journal of Human Genetics*, **2009**, 17, 336-43	5.3	24
52	DCTN1 mutations in Perry syndrome. *Nature Genetics*, **2009**, 41, 163-5	36.3	239
51	GRN 3'UTR+78 C>T is not associated with risk for Parkinson disease. *European Journal of Neurology*, **2009**, 16, 909-11	6	6
50	Glucosidase-beta variations and Lewy body disorders. *Parkinsonism and Related Disorders*, **2009**, 15, 414-6	5.6	32

49	Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. *Parkinsonism and Related Disorders*, **2009**, 15, 466-7	3.6	28
48	A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. *Parkinsonism and Related Disorders*, **2009**, 15, 627-32	3.6	77
47	Phactr2 and Parkinson's disease. *Neuroscience Letters*, **2009**, 453, 9-11	3.3	12
46	DRD3 Ser9Gly and HS1BP3 Ala265Gly are not associated with Parkinson disease. *Neuroscience Letters*, **2009**, 461, 74-5	3.3	10
45	Dopamine beta-hydroxylase -1021C>T association and Parkinson's disease. *Parkinsonism and Related Disorders*, **2008**, 14, 544-7	3.6	8
44	Genetic variation of Omi/HtrA2 and Parkinson's disease. *Parkinsonism and Related Disorders*, **2008**, 14, 539-43	3.6	53
43	Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. *Journal of Neural Transmission*, **2008**, 115, 1279-84	4.3	14
42	Lrrk2 R1628P in non-Chinese Asian races. *Annals of Neurology*, **2008**, 64, 472-3	9.4	18
41	Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred. *Movement Disorders*, **2007**, 22, 291-2	7	12
40	Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. *Movement Disorders*, **2007**, 22, 389-92	7	8
39	ELAVL4, PARK10, and the Celts. *Movement Disorders*, **2007**, 22, 585-7	7	19
38	Common variants in Parkinson's disease. *Movement Disorders*, **2007**, 22, 899-900	7	4
37	Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. *Mechanisms of Ageing and Development*, **2007**, 128, 378-82	5.6	51
36	Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis. *Journal of Neural Transmission*, **2007**, 114, 327-9	4.3	6
35	Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. *Acta Neuropathologica*, **2007**, 113, 601-6	14.3	45
34	Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. *Neurogenetics*, **2007**, 8, 95-102	3	34
33	Advancing stroke therapeutics through genetic understanding. *Current Drug Targets*, **2007**, 8, 850-9	3	11
32	Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. *Parkinsonism and Related Disorders*, **2007**, 13, 89-92	3.6	148

31	Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. *Parkinsonism and Related Disorders*, **2007**, 13, 340-2	3.6	27
30	Identification of potential protein interactors of Lrrk2. *Parkinsonism and Related Disorders*, **2007**, 13, 382-5	3.6	61
29	Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease. *Parkinsonism and Related Disorders*, **2007**, 13, 386-8	3.6	5
28	Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. *Parkinsonism and Related Disorders*, **2007**, 13, 509-15	3.6	39
27	A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. *Neuroscience*, **2007**, 147, 1047-58	3.9	96
26	Phenotypic associations of tau and ApoE in Parkinson's disease. *Neuroscience Letters*, **2007**, 414, 141-4	3.3	41
25	Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. *Neuroscience Letters*, **2007**, 416, 299-301	3.3	20
24	Lrrk2 mutations in South America: A study of Chilean Parkinson's disease. *Neuroscience Letters*, **2007**, 422, 193-7	3.3	17
23	Longevics: genetic lessons for the ages. *Irish Journal of Medical Science*, **2006**, 175, 82	1.9	4
22	Genomewide association, Parkinson disease, and PARK10. *American Journal of Human Genetics*, **2006**, 78, 1084-8; author reply 1092-4	11	50
21	Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. *Neuroscience Letters*, **2006**, 410, 80-4	3.3	46
20	Clinical heterogeneity of the LRRK2 G2019S mutation. *Archives of Neurology*, **2006**, 63, 1242-6		26
19	LRRK2 mutations are a common cause of Parkinson's disease in Spain. *European Journal of Neurology*, **2006**, 13, 391-4	6	46
18	Parkinson's disease: the genetics of a heterogeneous disorder. *European Journal of Neurology*, **2006** , 13, 616-27	6	38
17	Lrrk2 R1441 substitution and progressive supranuclear palsy. *Neuropathology and Applied Neurobiology*, **2006**, 32, 23-5	5.2	31
16	LRRK2 mutations and Parkinsonism. *Lancet, The*, **2005**, 365, 1229-30	40	28
15	Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. *American Journal of Human Genetics*, **2005**, 76, 672-80	11	453
14	Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. *Parkinsonism and Related Disorders*, **2005**, 11, 349-52	3.6	26

13	Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease. *Biochemical Society Transactions*, **2005**, 33, 586-90	5.1	35
12	LRRK2 mutations are not common in Alzheimer's disease. *Mechanisms of Ageing and Development*, **2005**, 126, 1201-5	5.6	27
11	Investigation of KIR diversity in immunosenescence and longevity within the Irish population. *Experimental Gerontology*, **2004**, 39, 1223-32	4.5	19
10	Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson's disease in the Irish. *Human Immunology*, **2004**, 65, 340-6	2.3	60
9	Linkage disequilibrium and association of MAPT H1 in Parkinson disease. *American Journal of Human Genetics*, **2004**, 75, 669-77	11	130
8	mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish. *Experimental Gerontology*, **2003**, 38, 397-405	4.5	91
7	Increased frequency of the 2437T allele of the heat shock protein 70-Hom gene in an aged Irish population. *Experimental Gerontology*, **2003**, 38, 561-5	4.5	33
6	Study of age-association with cytokine gene polymorphisms in an aged Irish population. *Mechanisms of Ageing and Development*, **2003**, 124, 199-206	5.6	62
5	Interleukin-6-gene C/G 174 polymorphism in nonagenarian and octogenarian subjects in the BELFAST study. Reciprocal effects on IL-6, soluble IL-6 receptor and for IL-10 in serum and monocyte supernatants. *Mechanisms of Ageing and Development*, **2003**, 124, 555-61	5.6	70
4	HLA haplotypes and TNF polymorphism do not associate with longevity in the Irish. *Mechanisms of Ageing and Development*, **2003**, 124, 563-7	5.6	32
3	Mitochondrial DNA damage in lymphocytes: a role in immunosenescence?. *Experimental Gerontology*, **2002**, 37, 329-40	4.5	31
2	Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. *Human Immunology*, **2002**, 63, 1055-61	2.3	136
1	Mitochondrial DNA polymorphism: its role in longevity of the Irish population. *Experimental Gerontology*, **2001**, 36, 1161-78	4.5	150